HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of optic neuritis with megadose corticosteroids.

Abstract
Difficulty in distinguishing between monosymptomatic optic neuritis due to autoimmune disease or to intrinsic demyelination in young adults prompted a trial administration of megadose corticosteroids in a series of patients. Treatment with 1 g daily of intravenous methylprednisolone (Solu-Medrol) for 2 to 5 days led to the rapid resolution and restoration of visual function in five patients. Two untreated patients suffered irreversible loss of vision. One patient with known autoimmune disease required a higher dose. The author suggests a trial of megadose, intravenous corticosteroids in patients between the ages of 21 and 45 years with optic neuropathies of uncertain or suspected autoimmune etiology after appropriate neuro-ophthalmologic evaluation.
AuthorsT C Spoor
JournalJournal of clinical neuro-ophthalmology (J Clin Neuroophthalmol) Vol. 6 Issue 3 Pg. 137-43 (Sep 1986) ISSN: 0272-846X [Print] United States
PMID2946719 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Adrenal Cortex Hormones
  • Prednisolone
Topics
  • Adrenal Cortex Hormones (administration & dosage, therapeutic use)
  • Adult
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Optic Neuritis (drug therapy, physiopathology)
  • Prednisolone (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: